Roche shares opened about 1.5% higher in Zurich on Monday after the Swiss drugmaker said its experimental lung cancer pill divarasib cut the risk of death by 44% against the two KRAS G12C drugs already on the market. The data extend a run that lifted the stock 11.7% in three weeks, to CHF 397.40 at Friday's close.
A head-to-head win against approved drugs
The Phase III Krascendo 1 trial compared divarasib with sotorasib or adagrasib, the two approved drugs that block the same KRAS G12C mutation, in 338 adults with advanced non-small cell lung cancer who had already been treated. Beating the existing standard is a harder test than beating chemotherapy or placebo, and a clear win suggests divarasib could take share in an established class rather than wait for a new one.
Patients on divarasib lived for a median of 17.7 months, against 12.0 months in the control arm, a hazard ratio of 0.56. The trial's main goal, progression-free survival judged by independent reviewers, also went divarasib's way: 9.8 months against 5.7 months, a 42% lower risk of the cancer growing or the patient dying. The confirmed response rate was 58%, close to double the 32% in the control arm.
Krascendo 1 trial
- -44% risk of death vs. sotorasib or adagrasib
- 17.7 months median survival, vs. 12.0 months
- 58% response rate, vs. 32%
Tolerability also favoured the Roche drug. Only 4.8% of patients on divarasib stopped treatment because of side effects linked to the drug, against 11.7% in the control arm, and serious treatment-related side effects ran at 7.8% against 15.2%. The most common problems were gastrointestinal and liver-related and mostly mild, and Roche said it saw no new safety signals.
The results were presented on Sunday as a late-breaking abstract in a Presidential Symposium at the ESMO congress in Madrid and published at the same time in the New England Journal of Medicine. The study's lead author, Ferdinandos Skoulidis, called divarasib "the first KRAS inhibitor to meaningfully improve overall survival".

Roche: share price, chart and news
What comes next for divarasib
Roche said it is working with health authorities to make the drug available but gave no timetable for filings. The US Food and Drug Administration granted divarasib Breakthrough Therapy Designation in 2022 and Orphan Drug Designation for this type of lung cancer in 2026.
The bigger commercial prize lies earlier in the disease. Krascendo 2 is testing divarasib with the immunotherapy pembrolizumab, without chemotherapy, as a first treatment against chemotherapy plus pembrolizumab. Krascendo 3 is testing it after surgery in stage II to IIIB disease. Neither has reported yet, and both would reach far more patients than the previously treated group in Krascendo 1.
Results set the tone last week
The trial news arrived four days after Roche's nine-month update. Group sales reached CHF 46.5bn, up 6% at constant exchange rates but only 1% in Swiss francs because of the strong franc. That currency drag reversed in the third quarter, when sales rose 7% at constant rates and 8% in francs.
Pharmaceuticals sales were CHF 36.2bn, up 7% at constant rates, and Diagnostics CHF 10.3bn, up 4%. Five medicines did most of the work: Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo together sold CHF 16.8bn, up 12%. Roche confirmed, rather than raised, its 2026 outlook for mid-single-digit sales growth and high-single-digit growth in core earnings per share at constant rates, and it still expects to raise its dividend in francs.
Investors did not need an upgrade. The shares rose 3.33% in the week to 23 October, after gains of 4.91% and 3.04% in the two weeks before, and Deutsche Bank upgraded the stock to Buy on 23 October.
What investors watch now
The first question is how much of the divarasib result was already in the price after three weeks of gains. The ESMO congress runs until Tuesday, so more cancer data will reach the market this week.
Beyond that, the market will look for a filing date for divarasib, for the first readouts from Krascendo 2 and 3, and for decisions on medicines already under review, including the US Priority Review for fenebrutinib in multiple sclerosis that Roche listed with its results. The Swiss franc remains the main swing factor for the reported numbers.
Sources
- Roche: Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
- Roche: Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF
- Swissinfo (Bloomberg): Roche Drug Beats Amgen, Bristol Rivals in Lung Cancer Study
- MarketScreener: Roche Holding AG news and analyst ratings
- BMK News market data (delayed exchange data)








